Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Purinostat mesylate + pomalidomide + low-dose dexamethasone in relapsed or refractory multiple myeloma
CTR20241633Phase 2Active
- Sponsor
- Zeling Biopharma
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of purinostat in multiple myeloma (MM), sponsored by Zeling Biopharma. Started Jun 2024; status: active.
02
Drugs
purinostat
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20241633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241633.